Literature DB >> 21320389

A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation.

Andre Russowsky Brunoni1, Joao Amadera, Bruna Berbel, Magdalena Sarah Volz, Brenno Gomes Rizzerio, Felipe Fregni.   

Abstract

Transcranial direct current stimulation (tDCS) is a non-invasive method of brain stimulation that has been intensively investigated in clinical and cognitive neuroscience. Although the general impression is that tDCS is a safe technique with mild and transient adverse effects (AEs), human data on safety and tolerability are largely provided from single-session studies in healthy volunteers. In addition the frequency of AEs and its relationship with clinical variables is unknown. With the aim of assessing tDCS safety in different conditions and study designs, we performed a systematic review and meta-analysis of tDCS clinical trials. We assessed Medline and other databases and reference lists from retrieved articles, searching for articles from 1998 (first trial with contemporary tDCS parameters) to August 2010. Animal studies, review articles and studies assessing other neuromodulatory techniques were excluded. According to our eligibility criteria, 209 studies (from 172 articles) were identified. One hundred and seventeen studies (56%) mentioned AEs in the report. Of these studies, 74 (63%) reported at least one AE and only eight studies quantified AEs systematically. In the subsample reporting AEs, the most common were, for active vs. sham tDCS group, itching (39.3% vs. 32.9%, p>0.05), tingling (22.2% vs. 18.3%, p>0.05), headache (14.8% vs. 16.2%, p>0.05), burning sensation (8.7% vs. 10%, p>0.05) and discomfort (10.4% vs. 13.4%, p>0.05). Meta-analytical techniques could be applied in only eight studies for itching, but no definite results could be obtained due to between-study heterogeneity and low number of studies. Our results suggested that some AEs such as itching and tingling were more frequent in the tDCS active group, although this was not statistically significant. Although results suggest that tDCS is associated with mild AEs only, we identified a selective reporting bias for reporting, assessing and publishing AEs of tDCS that hinders further conclusions. Based on our findings, we propose a revised adverse effects questionnaire to be applied in tDCS studies in order to improve systematic reporting of tDCS-related AEs.

Entities:  

Mesh:

Year:  2011        PMID: 21320389     DOI: 10.1017/S1461145710001690

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  269 in total

1.  No Effect of 2 mA Anodal tDCS Over the M1 on Performance and Practice Effect on Grooved Pegboard Test and Trail Making Test B

Authors:  Asbjørn J Fagerlund; Janita L Freili; Therese L Danielsen; Per M Aslaksen
Journal:  eNeuro       Date:  2015-08-31

2.  Efficacy and Safety of Transcranial Direct Current Stimulation for Treating Negative Symptoms in Schizophrenia: A Randomized Clinical Trial.

Authors:  Leandro da Costa Lane Valiengo; Stephan Goerigk; Pedro Caldana Gordon; Frank Padberg; Mauricio Henriques Serpa; Stephanie Koebe; Leonardo Afonso Dos Santos; Roger Alberto Marcos Lovera; Juliana Barbosa de Carvalho; Martinus van de Bilt; Acioly L T Lacerda; Helio Elkis; Wagner Farid Gattaz; Andre R Brunoni
Journal:  JAMA Psychiatry       Date:  2020-02-01       Impact factor: 21.596

Review 3.  Transcranial Direct Current Stimulation as a Therapeutic Tool for Chronic Pain.

Authors:  Camila Bonin Pinto; Beatriz Teixeira Costa; Dante Duarte; Felipe Fregni
Journal:  J ECT       Date:  2018-09       Impact factor: 3.635

4.  Multiple sclerosis fatigue relief by bilateral somatosensory cortex neuromodulation.

Authors:  Franca Tecchio; Andrea Cancelli; Carlo Cottone; Giancarlo Zito; Patrizio Pasqualetti; Anna Ghazaryan; Paolo Maria Rossini; Maria Maddalena Filippi
Journal:  J Neurol       Date:  2014-05-23       Impact factor: 4.849

5.  Personalized upper limb training combined with anodal-tDCS for sensorimotor recovery in spastic hemiparesis: study protocol for a randomized controlled trial.

Authors:  Mindy F Levin; Melanie C Baniña; Silvi Frenkel-Toledo; Sigal Berman; Nachum Soroker; John M Solomon; Dario G Liebermann
Journal:  Trials       Date:  2018-01-04       Impact factor: 2.279

6.  Noninvasive neurostimulation of left ventral motor cortex enhances sensorimotor adaptation in speech production.

Authors:  Terri L Scott; Laura Haenchen; Ayoub Daliri; Julia Chartove; Frank H Guenther; Tyler K Perrachione
Journal:  Brain Lang       Date:  2020-07-29       Impact factor: 2.381

7.  Neuromodulatory Effect of Transcranial Direct Current Stimulation on Resting-State EEG Activity in Internet Gaming Disorder: A Randomized, Double-Blind, Sham-Controlled Parallel Group Trial.

Authors:  Ji-Yoon Lee; Joon Hwan Jang; A Ruem Choi; Sun Ju Chung; Bomi Kim; Minkyung Park; Sohee Oh; Myung Hun Jung; Jung-Seok Choi
Journal:  Cereb Cortex Commun       Date:  2021-01-04

Review 8.  Neuromodulation for brain disorders: challenges and opportunities.

Authors:  Matthew D Johnson; Hubert H Lim; Theoden I Netoff; Allison T Connolly; Nessa Johnson; Abhrajeet Roy; Abbey Holt; Kelvin O Lim; James R Carey; Jerrold L Vitek; Bin He
Journal:  IEEE Trans Biomed Eng       Date:  2013-02-01       Impact factor: 4.538

9.  The use of magnetic resonance spectroscopy as a tool for the measurement of bi-hemispheric transcranial electric stimulation effects on primary motor cortex metabolism.

Authors:  Sara Tremblay; Vincent Beaulé; Sébastien Proulx; Louis-Philippe Lafleur; Julien Doyon; Małgorzata Marjańska; Hugo Théoret
Journal:  J Vis Exp       Date:  2014-11-19       Impact factor: 1.355

Review 10.  A technical guide to tDCS, and related non-invasive brain stimulation tools.

Authors:  A J Woods; A Antal; M Bikson; P S Boggio; A R Brunoni; P Celnik; L G Cohen; F Fregni; C S Herrmann; E S Kappenman; H Knotkova; D Liebetanz; C Miniussi; P C Miranda; W Paulus; A Priori; D Reato; C Stagg; N Wenderoth; M A Nitsche
Journal:  Clin Neurophysiol       Date:  2015-11-22       Impact factor: 3.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.